Radium-223 (Ra-223) is a radioactive isotope of radium. It is part of the actinide series and is produced through the decay of uranium and thorium. Radium-223 has a half-life of about 11.43 days and emits alpha particles as it decays. Radium-223 has been studied and used in the medical field, particularly in the treatment of metastatic prostate cancer that has spread to the bones.
Articles by others on the same topic
There are currently no matching articles.